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Abstract: The conformation of the activation loop (T-loop) of
protein kinases underlies enzymatic activity and influences the
binding of small-molecule inhibitors. By using single-molecule
fluorescence spectroscopy, we have determined that phos-
phorylated Aurora A kinase is in dynamic equilibrium
between a DFG-in-like active T-loop conformation and
a DFG-out-like inactive conformation, and have measured
the rate constants of interconversion. Addition of the Aurora A
activating protein TPX2 shifts the equilibrium towards an
active T-loop conformation whereas addition of the inhibitors
MLN8054 and CD532 favors an inactive T-loop. We show that
Aurora A binds TPX2 and MLN8054 simultaneously and
provide a new model for kinase conformational behavior. Our
approach will enable conformation-specific effects to be
integrated into inhibitor discovery across the kinome, and we
outline some immediate consequences for structure-based drug
discovery.
Protein kinases are essential for the regulation and signaling
of eukaryotic cells and are important drug targets in cancer
and inflammatory disease.[1] Many kinases are regulated by
phosphorylation of a regulatory Ser/Thr/Tyr residue on
a region of the kinase known as the activation loop or
T-loop. The influence of phosphorylation and interactions
with small-molecule inhibitors on kinase conformation can be
summarized by two models. In the first model, phosphoryla-
tion achieves activation by “locking” the activation loop in
a conformation where the catalytic residues are aligned
(Figure 1a).[2] In the second model, an inactive-conformation
kinase bound to a type II inhibitor (an inhibitor whose
binding site extends into a specific allosteric pocket adjacent
to the ATP-binding site) is in equilibrium with the ligand-free
kinase in an active conformation (Figure 1b). In the context
of these models, the active conformation is typified by the
activation loop being oriented to form the protein substrate
binding site and the aspartic acid of the conserved DFGmotif
at the beginning of this loop pointing into the ATP binding
site to coordinate Mg2+/ATP (DFG-in). In the classical
inactive conformation, both the activation loop and the
DFG motif are rotated by 1808, and a phenylalanine replaces
the aspartic acid in the ATP-binding pocket (DFG-out). Both
models have been supported by X-ray crystallography but
direct experimental testing of kinase activation loop mobility
has proved impossible to date as activation loop dynamics
occur on the same timescale as NMR intermediate
exchange.[3]
To test these models directly, we used single-molecule
fluorescence spectroscopy to monitor the conformation of the
kinase activation loop. We implemented our assay in
Aurora A kinase, a mitotic kinase whose catalytic activity
can be increased in the presence of its protein binding partner
TPX2[4] and inhibited with numerous drug-like small mole-
cules.[4d,5] Interest in Aurora A and its conformational plas-
ticity has recently increased owing to the discovery that
inhibiting Aurora Awith MLN8054 or CD532, both observed
to bind Aurora A in an inactive T-loop conformation, disrupts
the interaction of Aurora A with the proto-oncogenic tran-
scription factor N-Myc. This leads to degradation of N-Myc
and offers an alternative therapeutic strategy for N-Myc-
driven tumors (currently under clinical evaluation with
MLN8237/alisertib).[5d,6] These factors make Aurora A an
excellent clinically relevant system for studying the hetero-
geneity and dynamics of T-loop conformation underlying the
observed structural and catalytic properties of protein
kinases.
For clarity, we use the terms “active T-loop” and “inactive
T-loop” to refer to the two orientations of the activation loop
(Figure 1c,d; see also the Supporting Information, Fig-
ure S1a). We reserve the terms DFG-in and DFG-out for
discussions of the detailed orientation of the DFG motif
(Figure S1b).
We labeled a pseudo-wildtype construct of Aurora A
(C290A/C393A)[7] with tetramethylrhodamine (TMR) on
cysteine residues introduced into the activation loop
(S283C) and the N lobe of the kinase (K224C; Figure 1d).
The fluorescence of TMR is quenched when two molecules
are closer than about 15 , and this phenomenon has
previously been used to probe small distance changes at the
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single-molecule level.[8] Control reactions confirmed that only
two sites were available for coupling (Figure S2).
The catalytic activity of TMR-labeled phosphorylated
Aurora A is similar to that of the unlabeled pseudo-wildtype
protein (Figure 1e). We tethered labeled protein to a cover
slip via a His tag (Figure S4) and imaged the fluorescence
intensity by total internal reflection fluorescence (TIRF)
microscopy. Single-molecule fluorescence traces from double-
labeled Aurora A molecules were identified by the presence
of two-step photobleaching at their end.[9] Before photo-
bleaching, these molecules exhibited a single high fluores-
cence intensity and transiently entered a low-intensity,
quenched state (example trace in Figure 1 f), which we
interpret to indicate changes in the position of the Aurora A
T-loop: high fluorescence indicating an active-conformation
T-loop, and quenched fluorescence an inactive T-loop (see the
Experimental Methods Section in the Supporting Informa-
tion).
The fluorescence intensity histogram for phosphorylated
Aurora A shows two peaks, indicating that the kinase adopts
both active and inactive T-loop conformations (Figure 2a).
The relative areas of the peaks indicate that in solution the
majority of molecules adopt an active T-loop conformation
and a minority an inactive conformation (Table 1). This is
consistent with the active T-loop conformation observed in
X-ray structures of uninhibited kinase and with the high
catalytic activity of phosphorylated Aurora A.[4b] Contrary to
the model of a locked phosphorylated T-loop, our data
Figure 1. a) Current model of kinase activation: Phosphorylation on the activation loop (black line) locks the kinase in an active T-loop
conformation. b) Current equilibrium model of type II inhibitor binding: Active apo kinase is in equilibrium with inhibited kinase in an inactive
T-loop conformation. c) Proposed equilibrium model showing TMR-labeled sites (pink stars) and the expected fluorescence signal. d) Conforma-
tional change and labeling sites in Aurora A. Active T-loop: blue, inactive T-loop: pink. Activation loop shown in cyan/bright pink. Labeling sites
(K224 in orange and S283 in pink/cyan) shown as filled spheres. PDBs 1OL5 and 2WTV. e) Kinase activity assay for unlabeled pseudo-wildtype
Aurora A (&) and TMR-labeled K224C/S283C (~). Activity shown as the [ADP] produced over the course of a 1 h reaction. The difference in
activity between pseudo-wildtype and labeled protein cannot be accounted for by incomplete protein labeling (see the Supporting Information for
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indicate that the activation loop of phosphorylated Aurora A
exists in a dynamic structural equilibrium (Keq= 0.3 0.1).
It has been suggested that the free energy penalty of
interconverting between active and inactive conformations of
the tyrosine kinases Src and Abl underlies the selectivity of
type II inhibitors such as Imatinib, although this has been
challenged.[10] Consequently, there have been efforts to
calculate the free energy difference between these conforma-
tions. None of these studies explicitly distinguished between
the orientation of the DFG motif and the overall orientation
of the T-loop (usually assumed to be coupled); however, the
experimental protocols suggest that they report on the
Figure 2. Fluorescence intensity distribution for phosphorylated TMR-labeled K224C/S283C Aurora A. a) Intensity histogram of unliganded
Aurora A. b) Dwell time histogram of the quenched inactive T-loop conformation. c–k) Fluorescence intensity distributions with c) 1 mm ATP,
d) 3 mm kemptide, e) 1 mm AMP-PNP, f) 1 mm AMP-PNP and 3 mm kemptide, g) 5 mm TPX2, h) 5 mm TPX2, 1 mm AMPPNP, and 3 mm
Kemptide, i) 10 mm MLN8054, j) 10 mm CD532, and k) 5 mm TPX2 and 10 mm MLN8054. l) Summary of the conformational preferences of Aurora A
under different conditions. Error bars show propagated fitting errors.
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interconversion between DFG-in active T-loop and DFG-out
inactive T-loop conformations.[11] Our experimental measure-
ments report directly on the interconversion between active
and inactive T-loop conformations (without measuring the
orientation of the DFGmotif), and the free energy difference
that we obtained for phosphorylated Aurora A is 0.7
0.1 kcalmol1 (DGinactive–active). This is very similar to the
value of 0.8 kcalmol1 that has been measured for the two
unassigned conformations of phosphorylated Erk2[12] and
considerably less than the calculated values for Src.[11a,c]
We also measured the microscopic rate constant for
adopting an active T-loop conformation, kactive (Figure 2b;
kactive= 2.3 0.2 s1). We were unable to measure kinactive
directly as the observation time of individual molecules was
limited by photobleaching, but we calculated this to be 0.7
0.2 s1 from Keq.
To determine how kinase substrates influence the con-
formation of the activation loop, we measured fluorescence
intensity distributions of Aurora A in the presence of
saturating levels of ATP, kemptide (a 7-residue peptide
substrate), and AMP-PNP (a non-hydrolysable analogue of
ATP; Figure 2c–f). Neither kemptide nor AMP-PNP changed
the position of the equilibrium from that of unliganded kinase
while, surprisingly, ATP alone and AMP-PNP/kemptide both
slightly increased the population of the inactive T-loop
conformation (Table 1).
We next measured the intensity distribution of Aurora A
in the presence of the activator TPX2 (Figure 2g). Occupancy
of the active T-loop conformation was increased (Table 1),
consistent with the increased catalytic activity of the enzyme.
To build a picture of the enzyme poised for maximal activity,
wemeasured the distribution of the Aurora A–TPX2 complex
bound to AMP-PNP and kemptide (Figure 2h). This adopted
a predominantly active T-loop conformation, similar to that of
the Aurora A–TPX2 complex alone.
MLN8054 and CD532 are both nanomolar inhibitors of
Aurora A, and X-ray structures show that each binds in an
inactive T-loop conformation (Figure S1c,d).[5b,d,g] Although
both are referred to as type II inhibitors, neither extends into
the allosteric hydrophobic pocket, and neither has been
captured binding the kinase with a canonical DFG-out motif.
Aurora A bound to MLN8054 adopts an unusual DFG
conformation previously termed DFG-up,[5b] and Aurora A
bound to CD532 is DFG-in.[5d]
To determine the effect of these inhibitors on the
activation loop of Aurora A in solution, we repeated our
assay in their presence (Figure 2 i, j). Each inhibitor resulted
in a large increase in the population of the inactive T-loop
conformation, which is consistent with the crystal structures
(Table 1). Control measurements showed that neither inhib-
itor affected the peak fluorescence intensity of TMR,
although peak broadening was observed, particularly for
CD532 (Figure S5 and Table S1). The number of fluorescent
molecules in the field of view remained constant within each
control (35 6 kinase alone, 34 5 with MLN8054; n= 12).
As TPX2 and MLN8054 move the position of the
conformational equilibrium in opposing directions, we won-
dered how they interacted when present simultaneously. This
is a physiologically relevant scenario at the mitotic spindle,
and kinetic studies have shown that the presence of TPX2
increases theKi value of MLN8054 by a factor of greater than
four.[5b] Similar changes have been observed for VX680 and
GSK623906A.[4d] In the presence of both MLN8054 and
TPX2, Aurora A adopted a predominantly active T-loop
conformation, similar to that for TPX2 alone (Figure 2k and
Table 1).
To determine whether this result represents a mixture of
binary Aurora A–MLN8054 and Aurora A–TPX2 complexes
or population of an Aurora A–TPX2–MLN8054 triple com-
plex, we calculated the expected experimental result for the
mixture of binary complexes based on the published affinities
of the two ligands[4b,5b] (see the Supporting Information). A
mixture of binary complexes would result in an inactive
T-loop population of 43%, which is inconsistent with the
experimental result (15%; Table 1). Our experimental sam-
ples must thus contain a triple complex of Aurora A–TPX2–
MLN8054. We were unable to quantify the extent of triple
complex formation, but to account for the experimental
results, it must be the major species and must occupy a mainly
active T-loop conformation.
Our measurements indicate that phosphorylated
Aurora A is not locked into a single conformation, and that
Table 1: Occupancy of Aurora A conformations under different conditions.
Ligand(s) Ligand concentration
[mm]







[b] DGinactive–active at 25 8C
[kcalmol1][c]
Apo – – 23 77 0.3 0.7
MLN8054 10 0.0003[d] 43 57 0.7 0.2
CD532 10 0.048[e] 64 36 1.8 0.4
TPX2 5 0.01[f ] 14 86 0.2 1.1
TPX2/MLN8054 5/10 0.01[f ]/0.0003[d] 15 85 0.2 1.0
AMPPNP 1000 ND 22 78 0.3 0.7
ATP 1000 36[g] 32 68 0.5 0.5
Kemptide 3000 330[g] 21 79 0.3 0.8
AMPPNP/Kemptide 1000/3000 ND/330[h] 30 70 0.4 0.5
TPX2/AMPPNP/Kemptide 5/1000/3000 0.01[f ]/ND/330[h] 12 88 0.1 1.2
[a] The error of the loop occupancy is propagated from the fitting error of the histograms and is2. [b] Keq= [inactive T-loop]/[active T-loop]. The error
on Keq is propagated from the fitting error of the histograms and is <0.1. [c] DGinactive–active=RT ln(Keq). The error on DGinactive–active is propagated from
fitting errors of the histograms and is 0.1 kcalmol1. [d] Ki from Ref. [5b]. [e] IC50 from Ref. [5d]. [f ] EC50 from Ref. [4b]. [g] Km from Ref. [4b]. [h] Km
measured in this study (Figure S3) with an error of 70 mm. ND=not determined.
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it spontaneously interconverts between active and inactive
T-loop conformations in solution, even in the presence of
saturating quantities of the small-molecule inhibitors
MLN8054 and CD532 or of TPX2. To explain our results,
we hypothesized that either the ligand residence time is short
[and rearrangement of the activation loop occurred in the
unliganded kinase; Equations (1), (2), and (3)] or that
Aurora A bound to saturating quantities of ligand can
interconvert between T-loop conformations.
ActiveÐ InactiveGþinh HInactive-inh ð1Þ
ActiveÐ InactiveGþinh HInactive-inhÐ Inactive*-inh ð2Þ
ActiveÐ InactiveÐ Inactive*Gþinh HInactive*-inh ð3Þ
We tested this by using the Keq value of the kinase alone
and the known ligand Kd to predict the observed Keq value in
the presence of ligand (see the Supporting Information).
Equation (1), an equivalent scheme for TPX2, and Equa-
tions (2) and (3) (which postulate the presence of a second
sub-conformation, inactive*, within the inactive T-loop con-
formation) all predicted Keq values that were 2–4 orders of
magnitude different from those measured. We therefore
concluded that ligand-bound Aurora A interconverts
between T-loop conformations and modelled our data by
using Equation (4).
This surprising conclusion is supported by X-ray crystal-
lography. Three PDB structures (2WTV, 3H10, and 2X81)
show Aurora bound to MLN8054 or a similar compound in an
inactive T-loop conformation, while in a fourth, low-resolu-
tion structure (2WTW), the crystal packing is incompatible
with an inactive T-loop, and the MLN8054-bound kinase
adopts an active T-loop conformation.[5b] All four Aurora–
MLN8054 structures superpose within the N and C lobes of
the kinase, varying only in the orientation of the activation
loop and in the exact angle between the two lobes. The
position of MLN8054 relative to the N lobe is identical across
all structures, implying that no change in the binding mode of
the inhibitor is required for interconversion between active
and inactive T-loop conformations. We propose that 2WTW
and 2WTV represent two snapshots of the Aurora A–
MLN8054 conformational ensemble. Interconversion
between these two conformations is brought about by move-
ment of the activation loop without the inhibitor leaving the
binding site.
To determine whether the reported change in Ki of
MLN8054 upon addition of TPX2[5b] reflects a true change in
the Kd value of MLN8054, or whether it can be accounted for
by changes in the position of the conformational equilibrium
alone, we partitioned the Ki value for MLN8054 into con-
formation-specific dissociation constants (Equation (4) and
the Supporting Information for modeling). In the absence of
TPX2, Kd,active= 1.0 nm and Kd,inactive= 0.4 nm, while in the
presence of TPX2, these values are equal and remain
unchanged (within experimental accuracy) at 3.3 nm, indicat-
ing a genuine change in Kd for the Aurora A–TPX2 complex.
Our analysis (see the Supporting Information, Equa-
tion (S18)) also provides insight into the drivers of inactive
and active T-loop conformations. The position of the equilib-
rium for any binding partner depends on the Kd,active/Kd,inactive
ratio and the intrinsic position of the equilibrium for the
kinase (Keq,free, which is a constant for each protein). In other
words, the proportion of ligand-bound kinase molecules in an
inactive T-loop conformation is driven by the degree to which
an inhibitor can discriminate between inactive and active
T-loop conformations, not by the overall inhibitor–kinase
affinity.
Our reported measurements derive from in vitro experi-
ments. While the exact values that we have determined may
change in the cellular environment, we expect the principle of
conformational equilibria and the models of inhibitor binding
that we have established to translate into cell-based contexts.
Our results thus have a number of consequences for drug
discovery:
1) At least two Aurora A inhibitors bind a conformation of
the kinase (the active T-loop conformation) that had
previously not been expected. It is now possible to
measure (and thus develop validated prediction algo-
rithms for) the effect of an inhibitor on kinase conforma-
tional equilibria in solution.
2) Potent conformation-independent inhibitors need to bind
both active and inactive T-loop conformations, and
structure-based drug design may need to focus on
common features of these.
3) For inhibitors binding to the inactive T-loop conformation,
differential binding to this conformation should be
maximized. This is particularly important for inhibitors
designed to induce a specific conformation of the kinase in
order to disrupt a physiological interaction (e.g., Aurora A
with N-Myc). While the affinity for the active T-loop
conformation is retained, we expect to find a small
proportion of the complex (e.g., Aurora A–CD532–N-
Myc) in the active T-loop conformation, even at saturating
concentrations of inhibitor.
4) For those kinases where Keq,free! 1, an inactive T-loop
inhibitor must achieve greater discrimination between
active and inactive T-loop conformations than an inhibitor
for a kinase where Keq,free 1. Some inhibitors may thus
appear to be inactive T-loop inhibitors when bound to one
target and active T-loop inhibitors when bound to another,
potentially contributing to unexpected cellular pheno-
types. We predict that the kinase phosphorylation state
will also affect the value of Keq,free.
5) Modification of the target protein (e.g., by binding to
a physiological protein partner such as TPX2) can change
the binding affinity of an inhibitor beyond what would be
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predicted solely from a change in the position of the
conformational equilibrium. Distinguishing between
allosteric partners such as TPX2 and scaffolding partners
may be possible from X-ray structures, from enzyme
activity assays, or potentially by inference from physio-
logical function (e.g., catalytic activation vs. substrate
recruitment). This means that early decisions over the best
form of the enzyme to target are still important.
6) Success in allosteric disruption by using an ATP-compet-
itive small molecule to displace a conformation-specific
physiological ligand will depend on the properties of the
protein–protein interaction to be disrupted (Figure S6).
By carefully matching inhibitors and interactions, it may
be possible to achieve specificity between different bind-
ing partners of the same kinase. In practice, the limits of
this approach will need to be found experimentally.
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Dynamic Equilibrium of the Aurora A
Kinase Activation Loop Revealed by
Single-Molecule Spectroscopy Dye quenching and single-molecule fluo-
rescence spectroscopy were used to
monitor the conformation of the activa-
tion loop of Aurora A in solution. The
position of the equilibrium between
active and inactive conformations is
changed by kinase ligands. Simple
induced-fit or conformational-selection
models do not explain the data. This has
several consequences for drug design.
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